Royalty Pharma and Pharmakon Advisors completed the $375m investment in Geron.

Royalty Pharma, a company specializing in acquiring pharmaceutical royalties, and Pharmakon Advisors, an investment manager providing non-dilutive debt for the life sciences industry, completed the $375m investment in Geron, a commercial-stage biopharmaceutical company. “The substantial financial commitment of exceptional long-term partners like Royalty Pharma and Pharmakon Advisors strengthens our cash position and further solidifies our balance sheet, while providing flexibility to invest in our future. We believe that the terms reflect the significant commercial potential of RYTELO. The proceeds are expected to enable us to support the commercial launch of RYTELO in the U.S. and potential launch in the EU, complete our Phase 3 IMpactMF trial in relapsed/refractory myelofibrosis, invest in supply chain redundancy for RYTELO, and our general working capital requirements,” Michelle Robertson, Geron Executive Vice President and CFO.